CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...
Data from ongoing Actimab-A Phase 2 clinical trial highlighting efficacy, safety profile and clinical strategy as a single agent targeting CD33 in patients with AML Studies highlighting enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback